Is Selank Safe?
Based on available human and animal studies, Selank appears to have a favorable safety profile. Clinical trials evaluating Selank in individuals with generalized anxiety disorder (GAD) and neurasthenia have demonstrated anxiolytic effects comparable to conventional anxiolytics, while limiting many adverse effects often associated with benzodiazepines, such as excessive drowsiness or cognitive impairment [1]. Scientific reviews of Selank's pharmacology also describe it as a peptide with relatively low toxicity and good tolerability in research settings [2].
However, it should be emphasized that most published studies were relatively small, and many of them were conducted in Russia. Larger international clinical trials are needed to better assess its long-term safety profile.
Is the peptide Selank safe?
Current evidence suggests that Selank is generally well-tolerated in scientific studies. Unlike benzodiazepines, which directly activate specific receptor sites, Selank appears to modulate several biological systems related to mood, stress response, and cognitive functions. Research indicates it may influence GABA signaling, enkephalin metabolism, neurotrophic pathways, and immune mechanisms without inducing strong sedative effects [2–4].
Animal studies have also shown that Selank does not impair normal activity and may even reduce sedation when used with some anxiolytic substances [5]. Nevertheless, long-term safety data in humans remain limited.
Is Selank Dangerous?
Currently published research does not suggest that Selank is inherently dangerous when used under controlled research conditions. Clinical trials have generally reported good tolerability and a low number of adverse events [1,2].
At the same time, the lack of reported safety issues should not be interpreted as proof of complete safety. As long-term human studies are still limited, researchers continue to analyze Selank's effects on neurotransmitters, neuroplasticity, and immune system function. As with any research peptide, caution should be exercised when interpreting claims regarding its safety.
Selank Side Effects
Compared to many traditional anti-anxiety medications, Selank is associated with a relatively small number of reported side effects. Scientific reviews often highlight the absence of significant sedation, muscle relaxation, cognitive impairment, or dependence development, which are commonly observed with the use of benzodiazepines [1,2].
Some publications regarding peptides mention mild and transient nasal irritation following intranasal administration. However, serious adverse events have not been frequently reported in available studies. Due to the limited number of studies, the occurrence of rare or unusual side effects cannot be entirely ruled out.
Can Selank Cause Anxiety?
The main area of research on Selank is anxiety reduction, not its induction. Studies involving individuals with generalized anxiety disorder have shown improvement in anxiety symptoms, while animal studies have consistently demonstrated a decrease in anxiety-related behaviors [1,6].
No significant studies have indicated anxiety as a common side effect. However, it's important to remember that individual reactions to neuroactive compounds can vary, and some individuals may experience unexpected emotional or mood changes. These have not been recognized as typical outcomes in the scientific literature.
Can Selank Cause Insomnia?
Current research does not indicate insomnia as a frequent side effect of Selank. Some researchers suggest that Selank's impact on stress regulation and emotional balance may indirectly support healthy sleep patterns [7].
However, formal studies on sleep are still limited. As Selank can affect neurotransmitter systems involved in vigilance and cognitive functions, individual responses may vary. Based on current data, insomnia does not appear to be a frequently reported effect.
Does Selank cause hair loss?
Currently, there is no published scientific evidence linking Selank to hair loss. Clinical, experimental, and mechanistic studies have primarily focused on GABA signaling, enkephalin metabolism, neurotrophic factors, and immune regulation, rather than pathways related to hair growth or androgenic activity [2–4].
At this time, no scientific research suggests that Selank contributes to baldness or accelerated hair loss.
Is Selank addictive?
One of the most frequently discussed advantages of Selank is its apparent lack of addictive properties. Unlike benzodiazepines, which directly activate benzodiazepine receptors and can lead to tolerance and physical dependence, Selank appears to act through other biological pathways related to GABA modulation, endogenous opioid peptides, and neurotrophic signaling [2,3].
Published clinical and experimental studies have not reported evidence of addiction, compulsive use, or drug-seeking behaviors. However, it should be noted that the number of long-term studies is still limited compared to approved anti-anxiety medications.
Selank Withdrawal Symptoms
Current research has not identified a recognized withdrawal syndrome associated with Selank. Clinical studies and scientific reviews do not describe recurrent anxiety, physical dependence, or withdrawal symptoms similar to those observed with benzodiazepines [1,2].
However, due to the limited number of long-term studies, the lack of documented withdrawal symptoms should not be interpreted as definitive proof that such effects can never occur.
Does Selank Cause Euphoria?
Available data suggest that Selank is not a euphoric or intoxicating substance. Research has primarily focused on its anxiolytic, cognitive-enhancing, and neuroregulatory properties, rather than on recreational or psychoactive effects [1–4].
Scientists typically describe Selank as a peptide that supports emotional stability and reduces anxiety without causing euphoria, intoxication, or altered states of consciousness characteristic of recreational substances.
Is Selank detected in drug tests?
Currently, there is no evidence to suggest that Selank is included in standard drug tests used in the workplace, military, or routine toxicology screenings. Typical tests are designed to detect substances such as opioids, cannabinoids, cocaine metabolites, amphetamines, or benzodiazepines.
Because Selank is a synthetic peptide and does not belong to commonly studied drug groups, it is usually not included in routine testing. However, specialized laboratory analyses targeting peptides may be possible in research, forensic, or anti-doping environments.
Summary
Current research suggests that Selank has a favorable safety profile and is generally well-tolerated under controlled study conditions. Studies have shown low toxicity, minimal sedative effects, and a lack of dependence-related effects compared to many traditional anxiolytics. Furthermore, common issues such as hair loss, significant withdrawal symptoms, or psychoactive effects have not been identified.
Despite promising results, the available clinical data remains relatively small. Further research involving larger participant groups is needed to better assess long-term safety, rare adverse events, and effects in diverse populations.
Disclaimer
This article is for educational and informational purposes only. Selank remains a research peptide in many countries, and scientific knowledge regarding its long-term safety is still evolving. The information presented is a summary of clinical, preclinical, and mechanistic study findings and should not be interpreted as medical advice, therapeutic recommendation, or confirmation of safety or efficacy.
For research purposes only: Selank products available at Semax Polska are intended exclusively for laboratory and scientific research. They are not approved for human consumption or for medical, diagnostic, therapeutic, or preventive use. All research materials should be used in accordance with applicable laws and laboratory research standards.
References
[1] Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Y., Serebriakova, E. V., Siranchieva, O. A., Andriushenko, A. V., Telesheva, E. S., Siuniakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and Neurasthenia. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. https://pubmed.ncbi.nlm.nih.gov/18454096/
[2] Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. F. (2018). Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642
[3] Zozulya, A. A., Kost, N. V., Sokolov, O. Y., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., Zolotarev, Y. A., Ivanov, S. V., Andryushchenko, A. V., Myasoedov, N. F., & Smulevich, A. B. (2001). The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity. Bulletin of Experimental Biology and Medicine, 131(4), 315–317. https://doi.org/10.1023/A:1017979514274
[4] Levitskaya, N. G., Andreeva, L. A., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal Administration of the Peptide Selank Regulates BDNF Expression in Rat Hippocampus In Vivo. Doklady Biological Sciences, 431, 79–82.
[5] Kost, N. V., Sokolov, O. Y., Zozulya, S. A., & Myasoedov, N. F. (2025). Combined Action of Benzodiazepine Tranquilizers and Peptide Anxiolytic Selank in BALB/c Mice. Neurochemical Journal, 19, 743–748. https://doi.org/10.1134/S1819712425700783
[6] Czabak-Garbacz, R., Cygan, B., Wolański, Ł., & Kozlovsky, I. (2006). Influence of Long-Term Treatment with Tuftsin Analogue TP-7 on Anxiety-Phobic States and Body Weight. Pharmacological Reports, 58(4), 562–567. PMID: 16963804.
[7] Vitiello, M. V., Schwartz, R. S., Moe, K. E., Mazzoni, G., & Merriam, G. R. (2001). Treating Age-Related Changes in Somatotropic Hormones, Sleep, and Cognition. Dialogues in Clinical Neuroscience, 3(3), 229–236. https://doi.org/10.31887/DCNS.2001.3.3/mvvitiello